IP Library Granted Patent US 12,303,614
Granted Patent B2
US 12,303,614 · App. 18/311,592 · Granted May 20, 2025

Compositions and methods for improving mechanical properties of a tissue or for regenerating an injured or diseased tissue

Inventor: Catherine K. Kuo (College Park, MD)
Assignee: University of Rochester
A61L27/24A61B5/0048A61L27/3834A61L27/54A61L2300/254A61L2300/414A61L2430/06A61L2430/10A61L2430/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,614
App. No.
18/311,592
Granted
May 20, 2025
Kind
B2
Abstract

The present invention relates to enhancing mechanical properties of tissue such as collagenous or collagen-containing or elastin-containing tissue (e.g., tendons, ligaments, and cartilage) and treating related musculoskeletal and non-musculoskeletal conditions or injuries.

Claims (24)

1. A pharmaceutical composition comprising

(i) lysyl oxidase (LOX) or LOX like (LOXL) protein (LOX/LOXL) enhancer selected from the group consisting of a LOX polypeptide, a LOXL protein, a pre-proLOX polypeptide, a proLOX polypeptide, a nucleic acid encoding one or more of the polypeptides, an engineered cell expressing or having said nucleic acid, and a viral particle having the nucleic acid,

(ii) an agent selected from the group consisting of BMP-1, Fibronectin, Tolloid, Vitamin B6, Ascorbic acid, and Procollagen c proteinase, and

(iii) a pharmaceutically acceptable carrier or excipient.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated in an ointment, a salve, a gel, a cream, a scaffold, or a microparticle.

3. A kit comprising

a LOX/LOXL enhancer selected from the group consisting of a LOX polypeptide, a LOXL protein, a pre-proLOX polypeptide, a proLOX polypeptide, a nucleic acid encoding one or more of the polypeptides, an engineered cell expressing or having said nucleic acid, and a viral particle having the nucleic acid,

an agent selected from the group consisting of BMP-1, Fibronectin, Tolloid, Vitamin B6, Ascorbic acid, and Procollagen c proteinase, and

a packaging material.

4. A method for (i) improving a mechanical property of a tissue or a component thereof in a subject or (ii) regenerating an injured or diseased tissue or developing embryonic/fetal tissue or a component thereof in a subject or (iii) enhancing mechanical properties of a healthy tissue in a subject, comprising (a) applying a mechanical stimulation to the tissue or cells therein and (b) administering to the subject the pharmaceutical composition of claim 1 .

5. The method of claim 4 , wherein said mechanical stimulation comprises one or more of a dynamic stimulation, a cyclic stimulation, a static stimulation, a deformation, a tensile stimulation, a compressive stimulation, a torsion stimulation, a shear stimulation, substrate stiffness, a mechanical loading, a static loading, a dynamic loading, a cyclic loading, a compression, shear, torsion, and deformation.

6. The method of claim 4 , wherein the tissue is a natural tissue, an engineered tissue, an embryonic tissue, a postnatal tissue, a tissue in vitro, or a tissue in vivo.

7. The method of claim 6 , wherein the tissue is a collagenous or collagen-containing tissue.

8. The method of claim 4 , wherein the mechanical property is selected from the group consisting of elastic modulus, tensile strength, torsional strength, elongation to break, hardness, compressive strength, burst strength, toughness, impact strength, torsion, failure load, and stiffness.

9. The method of claim 4 , further comprising administering a population of cells to the tissue.

10. The method of claim 9 , wherein the cells are (i) collagen-producing or elastin-producing cells or progenitor cells thereof or (ii) engineered to release a specific factor that directly or indirectly promotes LOX/LOXL or pro-LOX/pro-LOXL gene expression, LOX/LOXL or pro-LOX/pro-LOXL protein expression, or LOX/LOXL enzyme activity.

11. A method for (i) improving a mechanical property of a tissue or a component thereof in a subject or (ii) regenerating an injured tissue, a diseased or developing embryonic/fetal tissue, or a component thereof in a subject, comprising administering to the subject the pharmaceutical composition of claim 1 .

12. The method of claim 11 , wherein the tissue is a natural tissue, an engineered tissue, a tissue in vitro, or a tissue in vivo.

13. The method of claim 12 , wherein the tissue is a collagenous or collagen-containing tissue or an elastin-containing tissue.

14. The method of claim 11 , wherein the mechanical property is selected from the group consisting of elastic modulus, tensile strength, torsional strength, elongation to break, hardness, compressive strength, burst strength, toughness, impact strength, torsion, failure load, and stiffness.

15. The method of claim 11 , further comprising administering a population of cells to the tissue.

16. The method of claim 15 , wherein the cells are (i) collagen-producing cells, elastin-producing cells or progenitor cells thereof or (ii) engineered to release a specific factor that directly or indirectly promotes LOX/LOXL gene expression, LOX/LOXL protein expression, or LOX/LOXL enzyme activity.

17. The method of claim 4 , wherein this tissue is a tendon tissue or a ligament tissue.

18. The method of claim 11 , wherein this tissue is a tendon tissue or a ligament tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2025
From: KUO, CATHERINE K.
To: UNIVERSITY OF ROCHESTER
Reel/Frame 070944/0523 →
Continuity (3)
Division 16800151 · Feb 25, 2020
Provisional Application 62810021 · Feb 25, 2019
Related Publication 20240009350A1 · Jan 11, 2024
References Cited (24)
US 11679178B2 · Kuo · 2023 [cited by examiner]
US 20010016772A1 · Lee et al. · 2001 [cited by applicant]
US 20040067833A1 · Talish et al. · 2004 [cited by applicant]
US 20050025838A1 · Badylak · 2005 [cited by applicant]
US 20060029588A1 · Li et al. · 2006 [cited by applicant]
US 20060293724A1 · Kronberg et al. · 2006 [cited by applicant]
US 20080274545A1 · Kuo et al. · 2008 [cited by applicant]
US 20100047309A1 · Lu et al. · 2010 [cited by applicant]
US 20110293685A1 · Kuo et al. · 2011 [cited by applicant]
US 20170312392A1 · Guilak et al. · 2017 [cited by applicant]
US 20180155447A1 · Fan et al. · 2018 [cited by applicant]
WO 14065863A1 · 2014 [cited by applicant]
WO 2017087754A2 · 2017 [cited by applicant]
Brown et al., “Comparative analysis of mesenchymal stem cell and embryonic tendon progenitor cell response to embryonic tendon biochemical and mechanical factors,” Stem Cell Research & Therapy (2015); 6:89—8 pages. [cited by applicant]
Marturano et al., “Embryonically inspired scaffolds regulate tenogenically differentiating cells,” Journal of Biomechanics (2016); 49:3281-3288. [cited by applicant]
Marturano et al., “Lysyl oxidase-mediated collagen crosslinks may be assessed as markers of functional properties of tendon tissue formation,” Acta Biomaterialia (2014); 10:1370-1379. [cited by applicant]
Marturano et al., “Characterization of mechanical and biochemical properties of developing embryonic tendon,” PNAS (2013); 110(16):6370-6375. [cited by applicant]
Kuo et al., “Mechanoactive Tenogenic Differentiation of Human Mesenchymal Stem Cells,” Tissue Engineering: Part A (2008); 14:1615-1627. [cited by applicant]
Ng et al., “Estabilishing the Basis for Mechanobiology-Based Physical Tehrapy Protocols to Potentiate Cellular Healing and Tissue Regeneration,” Frontiers in Biology (2017); 8:Article 303—13 pages. [cited by applicant]
Bhuvanasundar et al., “A molecular model of human Lysyl Oxidase (LOX) with optimal copper orientation in the catalytic cavity for induced fit docking studies with potential modulators,” Biomedical Informatics (2014); 10… [cited by applicant]
Csiszar, Katalin, “Lysyl Oxidases: A Novel Multifunctional Amine Oxidase Family,” Progress in Nucleic Acid Research and Molecular Biology (copyright 2001); 70:1-32. [cited by applicant]
Cai et al., “The Role of the Lysyl Oxidases in Tissue Repair and Remodeling: A Consise Review,” Tissue Eng Regen Med (2017); 14(1):15-30. [cited by applicant]
Chica et al., “Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design,” Current Opinion in Biotechnology (2005); 16:378-384. [cited by applicant]
Singh et al., “Protein Engineering Approaches in the Post-Genomic Era,” Current Protein and Peptide Science (2017); 18:1-11. [cited by applicant]